Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | KIF11 | P52732 | 3/20 | 0.44 |
| ▸ | PEPD | P12955 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18519525 | 0.85 | CA12 (0.49) | CA1CA12CA14CA7CA2 | |
| SCHEMBL8237935 | 0.84 | CA12 (0.50) | CA1CA12CA14CA7CA2 | |
| SCHEMBL12107288 | 0.82 | CA12 (0.49) | CA1CA12CA14CA7CA2 | |
| SCHEMBL8246618 | 0.82 | CA12 (0.49) | CA1CA12CA14CA7CA2 | |
| SCHEMBL16038956 | 0.82 | CA12 (0.62) | CA1CA12CA14CA7CA2 | |
| SCHEMBL18028464 | 0.81 | KIF11 (0.54) | CA1CA12KIF11PEPDALDH1A1 | |
| SCHEMBL22638581 | 0.81 | CA12 (0.51) | CA1CA12CA14CA7CA2 | |
| SCHEMBL24667477 | 0.80 | HPGD (0.54) | CA1CA12CA14CA7CA2 | |
| SCHEMBL8244234 | 0.80 | CA12 (0.53) | CA1CA12CA14CA7CA2 | |
| SCHEMBL4892802 | 0.78 | CA1 (0.58) | CA1CA12CA14CA7CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | CA1 1754/4885CA12 1331/4885CA14 765/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | CA1 1754/4885CA12 1331/4885CA14 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.